Skip to main content
SpringerLink
Log in

Comparison of Salmeterol/Fluticasone Propionate Combination with Budesonide in Patients with Mild-to-Moderate Asthma

  • Clinical Use
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective

To compare the efficacy and tolerability of a salmeterol/fluticasone propionate (FP) combination product (50/100μg twice daily) with budesonide (BUD) at a four-fold higher microgram dose (400μg twice daily) in patients with mild-to-moderate asthma uncontrolled on existing therapy.

Design

This was a multicentre, randomised, double-blind, double-dummy, parallel-group study consisting of a 2-week run-in and a 12-week treatment period.

Interventions

Symptomatic patients (n = 349) received either the salmeterol/FPcombination (50/100μg twice daily; Diskus™) or BUD (400μg twice daily; Turbuhaler™).

Results

The salmeterol/FP combination group showed a significantly greater increase in mean morning (p = 0.022) and evening (p = 0.008) peak expiratory flow (PEF) compared with the BUD group. After 12 weeks of treatment, patients in the combination group had a mean PEF of 426 L/min (am) and 435 L/min (pm) compared with 415 L/min (am) and 424 L/min (pm) in the BUD group. The significant benefit of the combination product was evident from day one for both morning (p < 0.001) and evening (p = 0.002) PEF. Both treatments were well tolerated, and no difference was observed between the groups in improved symptom scores, use of rescue medication, clinic spirometry and exacerbations.

Conclusions

This study showed that the salmeterol/FP combination product was at least as effective as a four-fold higher microgram dose of BUD, with greater, and more rapid, improvement in morning and evening PEF. Therefore, in patients with mild-to-moderate asthma, symptomatic on existing therapy, the salmeterol/FP combination is an effective alternative to increasing the dose of inhaled corticosteroids, without the need for an additional inhaler.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996 May; 153(5): 1481–8

    PubMed  CAS  Google Scholar 

  2. Van Noord JA, Schreurs AJM, Mol SJM, et al. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999 Mar; 54(3): 207–12

    Article  Google Scholar 

  3. Condemi JJ, Goldstein S, Kalberg C, et al. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann Allergy Asthma Immunol 1999 April; 82(4): 383–9

    Article  PubMed  CAS  Google Scholar 

  4. Ind PW, Dal Negro R, Colman N, et al. Inhaled fluticasone propionate and salmeterol in moderate adult asthma. I. Lung function and symptoms [abstract]. Am J Respir Crit Care Med 1998 Mar; 157(3): A416

    Google Scholar 

  5. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997 Nov 13; 337(20): 1405–11

    Article  PubMed  CAS  Google Scholar 

  6. Ind PW, Dal Negro R, Colman C, et al. Inhaled fluticasone propionate and salmeterol in moderate adult asthma. II. Exacerbations [abstract]. Am J Respir Crit Care Med 1998 Mar; 157(3): A415

    Google Scholar 

  7. Global Initiative for Asthma. National Institutes of Health, National Heart, Lung and Blood Institute. Publication number 95-3659. 1995; Chapter 7: 70-117

  8. Chapman KR, Ringdal N, Backer V, et al. Salmeterol and fluticasone propionate (50/250 μg) administered via combination Diskus inhaler: As effective as when given via separate Diskus inhalers. Can Respir J 1999 Jan/Feb; 6(1): 45–51

    PubMed  CAS  Google Scholar 

  9. Aubier M, Pieters WR, Schlosser NJJ, et al. Salmeterol/ fluticasone propionate (50/500Xg) in combination in a Diskus inhaler (Seretide™) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999 Dec; 93(12): 876–84

    Article  PubMed  CAS  Google Scholar 

  10. Bateman ED, Britton M, Carrillo T, et al. Salmeterol/fluticasone combination inhaler. A new, effective and well tolerated treatment for asthma. Clin Drug Invest 1998 Sep; 16(3): 193–201

    Article  CAS  Google Scholar 

  11. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50μg and fluticasone propionate 250μg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000 Feb; 161 (2 Pt 1): 527–34

    PubMed  CAS  Google Scholar 

  12. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, doubleblind, placebo-controlled trial. J Allergy Clin Immunol 2000 June; 105 (6 Pt 1): 1108–16

    Article  PubMed  CAS  Google Scholar 

  13. Barnes NC, Hallett C, Harris TA. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med 1998 Jan; 92(1): 95–104

    Article  PubMed  CAS  Google Scholar 

  14. Murray JJ, Church NL, Anderson WH, et al. Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc 1999 May–Jun; 20(3): 73–180

    Article  Google Scholar 

  15. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994 July 23; 344(8917): 219–24

    Article  PubMed  CAS  Google Scholar 

  16. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992 Feb 20; 326(8): 501–6

    Article  PubMed  CAS  Google Scholar 

  17. Sears MR, Taylor DR, Print CG, et al. Regular inhaled betaagonist treatment in bronchial asthma. Lancet 1990 Dec 8; 336(8728): 1391–6

    Article  PubMed  CAS  Google Scholar 

  18. McIvor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998 Sep; 158(3): 924–30

    PubMed  CAS  Google Scholar 

  19. Britton MG, Earnshaw JS, Palmer JB. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992 Oct; 5(9): 1062–7

    PubMed  CAS  Google Scholar 

  20. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000 May 20; 320(7246): 1368–73

    Article  PubMed  CAS  Google Scholar 

  21. Johnson M. Pharmacology of long-acting beta-agonists. Ann Allergy Asthma Immunol 1995 Aug; 75(2): 177–9

    PubMed  CAS  Google Scholar 

  22. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 1998; 101: S434–9

    Article  PubMed  CAS  Google Scholar 

  23. Eickelberg O, Roth M, Lorx R, et al. Ligand-independent activation of the glucocorticoid receptor by β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999 Jan 8; 274(2): 1005–10

    Article  PubMed  CAS  Google Scholar 

  24. Chung KF, Dent G, Barnes PJ. Effects of salbutamol on bronchoconstriction, bronchial hyperresponsiveness, and leucocyte responses induced by platelet activating factor in man. Thorax 1989 Feb; 44(2): 102–7

    Article  PubMed  CAS  Google Scholar 

  25. Baraniuk JN, Ali M, Brody D, et al. Glucocorticoids induce β2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 1997 Feb; 155(2): 704–10

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nyby Vardcentral, Topeliusgatan 18, S-754 41, Uppsala, Sweden

    Gunnar Johansson

  2. Sunnybrook Health Science Centre, Toronto, Canada

    R. Andrew Mclvor

  3. Policlinico Universitario di Messina, Messina, Italy

    Francesco Purello D'Ambrosio

  4. Evenidion Hospital, Athens, Greece

    Christina Gratziou

  5. GlaxoSmithKline, Uxbridge, United Kingdom

    Mark H. James

Authors
  1. Gunnar Johansson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Andrew Mclvor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Purello D'Ambrosio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christina Gratziou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mark H. James
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johansson, G., Mclvor, R.A., D'Ambrosio, F.P. et al. Comparison of Salmeterol/Fluticasone Propionate Combination with Budesonide in Patients with Mild-to-Moderate Asthma. Clin. Drug Investig. 21, 633–642 (2001). https://doi.org/10.2165/00044011-200121090-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200121090-00005

Keywords

Search

Navigation